Anthem Inc. (NYSE: ANTM) reported a 2% decline in earnings for the first quarter of 2020 due to an increase in income tax expenses as well as higher costs and expenses. The top-line jumped by 21% driven by pharmacy product revenue related to the launch of IngenioRx as well as higher premium revenue.
For full-year 2020, the company expects GAAP EPS to be greater than $21 and adjusted EPS to be greater than $22.30. The company is withdrawing all other guidance metrics for 2020 until visibility improves from the unprecedented uncertainty around the COVID-19 pandemic. In response to the COVID-19 pandemic, the company has temporarily suspended share repurchase activity to enhance liquidity and financial flexibility.
Past Performance
ANTM Q4 2019 Earnings Infographic
Anthem Q3 2019 Earnings Results
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
